Get the Stockscreener App
48.87
4.56%
2.13
Cytokinetics Inc stock is traded at $48.87, with a volume of 3.36M.
It is up +4.56% in the last 24 hours and down -1.99% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$46.74
Open:
$46.85
24h Volume:
3.36M
Relative Volume:
2.86
Market Cap:
$5.77B
Revenue:
$3.22M
Net Income/Loss:
$-576.40M
P/E Ratio:
-8.8533
EPS:
-5.52
Net Cash Flow:
$-407.05M
1W Performance:
+0.45%
1M Performance:
-1.99%
6M Performance:
-5.69%
1Y Performance:
+36.81%
1-Day Range:
$46.85
$50.32
1-Week Range:
$45.66
$50.32
52-Week Range:
$36.24
$110.25
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
48.87 | 5.77B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Given New $82.00 Price Target at Royal Bank of Canada - MarketBeat
Cytokinetics CFO to assume additional role after officer departs By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Wendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics director Wendall Wierenga sells $36,068 in stock By Investing.com - Investing.com Canada
Cytokinetics CFO to assume additional role after officer departs - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock By Investing.com - Investing.com UK
A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Simply Wall St
Cytokinetics director John Henderson sells $89,747 in stock By Investing.com - Investing.com Australia
Cytokinetics director John Henderson sells $89,747 in stock - Investing.com India
Insider Sell: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $369,639 By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells shares worth $369,639 - Investing.com India
Two Sigma Advisers LP Makes New $11.34 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Reduces Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
FDA Sets Goal Date for Lymphoma Drug Columvi - Managed Healthcare Executive
Redmile Group LLC Sells 14,751 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Melqart Asset Management UK Ltd - MarketBeat
HighVista Strategies LLC Invests $531,000 in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Grants New Hires $1.8M+ Stock Options and RSU Package as Employment Incentive | CYTK Stock News - StockTitan
FDA Sets Goal Date for Cardiomyopathy Drug, Aficamten - Managed Healthcare Executive
FDA Accepts Cytokinetics' Application for Cardiovascular Drug - Yahoo Finance
Daily Digest: Sale of former Raiders HQ falls through; Oakland's credit rating cut - The Business Journals
Stock Watch: AHA Conference Disappointments - Scrip
Cytokinetics Launches Major Phase 3 Heart Failure Trial with 1,800 Patient Target | CYTK Stock News - StockTitan
FDA kicks off review of Cytokinetics' aficamten for HCM - pharmaphorum
Erste Asset Management GmbH Invests $3.16 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
FDA accepts Cytokinetics' New Drug Application for HCM By Investing.com - Investing.com Canada
The Manufacturers Life Insurance Company Boosts Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Present at Evercore ISI and Piper Sandler Healthcare Conferences - StockTitan
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics' HCM Drug Aficamten Advances with FDA Filing Acceptance, 2025 Review Date - StockTitan
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date - Yahoo Finance
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WIERENGA WENDALL | Director |
Dec 16 '24 |
Sale |
48.61 |
742 |
36,069 |
24,559 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):